Controlling timing and location in vaccines.

Authors:
Irvine DJ; Aung A; Silva M.

Journal:
Adv Drug Deliv Rev

Publication Year: 2020

DOI:
10.1016/j.addr.2020.06.019

PMCID:
PMC7318960

PMID:
32598970

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This was work was supported in part by the Ragon Institute of MGH, MIT, and Harvard, the NIH (awards UM1AI144462, AI048240, AI125068, CA247632, EB025854), the Marble Center for Nanomedicine, and the Dept. of Defense (contract W911NF-18-2-0048). DJI is an investigator of the Howard Hughes Medical Institute. MS is an NRSA Fellow (T32 AI07386)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025